cyrilzakka/clinical-trials huggingface dataset:
Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure

The purpose of the study is to compare the effects of conivaptan and diuretics on renal blood flow and neurohormones.

1. To define the hemodynamic, neurohormonal and renal responses to intravenous conivaptan in patients with chronic stable heart failure (HF), and compare these responses to those after intravenous furosemide.
2. To define the hemodynamic, neurohormonal and renal responses to the combination of the two drugs (conivaptan and furosemide).

Eligibility Criteria:
Inclusion Criteria:

* Have a diagnosis of chronic congestive heart failure of any etiology
* Be between 18-80 years of age
* Able to provide consent
* Have a documented left ventricular ejection fraction within the last year of \< 40%
* On a stable dose (no changes within 2 weeks) of 40 mg or greater daily dose of furosemide or its equivalent
* On standard HF therapy medications (ACEI or ARB and beta-blocker unless contraindicated)
* Have an estimated glomerular filtration rate (GFR) of 30 ml/minute or greater (based on the Cockcroft Gault calculation)
* Have a hemoglobin of \> 10 grams/dl
* Have a negative urine pregnancy for women of childbearing years only

Exclusion Criteria:

* Acute coronary syndrome within 1 month
* Systolic blood pressure less than or equal to 90 mmHg at time of enrollment
* Poor peripheral venous access
* Severe concomitant disease which deemed by the investigator would render them unsuitable for this trial
* Allergy or contraindication to the use of iothalamate, PAH - Specifically any allergies to iodine or iodine containing products, history of asthma and hay fever which deemed by the investigator would render them unsuitable for this trial
Bioavailability, Pharmacokinetics and Safety Evaluation of Phencynonate Hydrochloride in Healthy Volunteers

The purpose of this study is to evaluate the bioavailability of two formulations (Taiwan and China mainland) of phencynonate hydrochloride tablets and to generate pharmacokinetic and safety profiles of phencynonate hydrochloride in healthy volunteers.


Eligibility Criteria:
Inclusion Criteria:

1. Subjects must have signed and dated informed consent form.
2. Subjects must be ≧ 18 and ≦ 40 years old, healthy, non-smoking male.
3. Subjects with body weight within ± 20% ideal body weight
4. Subjects with urinalysis data within acceptable range, including pH, blood, glucose and protein
5. Subjects with laboratory evaluations data within acceptable range, including serum chemistry examinations (glucose, total cholesterol, TG, SGOT, SGPT, GSP, alkaline phosphatase, total bilirubin, total protein, albumin, r-GT, BUN, creatinine, uric acid) and hematology (complete blood count and platelets)
6. Subjects with acceptable ECG and chest x-ray

Exclusion Criteria:

1. Subjects had taken any drugs within 14 days prior to screening.
2. Subjects with history of glaucoma
3. Subjects with history of ileus
4. Subjects with history of benign prostate hypertrophy with urine retention
5. Subjects with history of myasthenia gravis
6. Subjects with history of asthma
7. Subject with history of any other medical conditions that, in the opinion of the investigator, compromised subject safety or ability to comply with study procedures
8. Subjects with history of drug or alcohol addiction or abuse within 1 year prior to screening
9. Subjects with hypersensitivity to phencynonate hydrochloride or other drugs with similar chemical structure
10. Subjects had donated blood more than 250 mL within the pervious 3 months prior to study
11. Subjects had received any investigational drugs within 1 month prior to screening
The CIRE Study (CItrate REcirculation Study)

The aim of this study is to determine the effects of AV port reversal (AVPR) on recirculation, clearance, post-filter ionized calcium and subsequently citrate dosing.

Rationale:

AV port reversal (AVPR) has been demonstrated to increase recirculation in venous catheters used in ICU for CVVH. The effects of this frequently used manoeuvre have not been described in the setting of CVVH using regional citrate anticoagulation.

Objective:

The aim of this study is to determine the effects of AVPR on recirculation, clearance, post-filter ionized calcium and subsequently citrate dosing.

Study design and methods:

Open trial studying the effect of AVPR in patients undergoing citrate CVVH. After measurement in standard catheter configuration, AVPR is performed after which effects on catheter recirculation, clearance, citrate dosing and post-filter ionized calcium (iCa) are monitored.

Sample sites:

Arterial line, arterial (pre-filter) port, postfilter port (after postdilution and calcium compensation), effluent sample. All flow rates to be noted.

Study population:

Twelve patients admitted to intensive care, requiring continuous renal replacement therapy (CRRT) for AKI. Patients are preferably anuric and have achieved good metabolic control under CVVH before inclusion in the study.

Eligibility Criteria:
Inclusion Criteria:

* Critically ill patients requiring CRRT for AKI (RIFLE criteria)
* Written informed consent from the patient or legal representative
* No AV port reversal had taken place before inclusion in the study
* Diuresis is minimal or the patient is anuric so that effects of changes in clearance as a consequence of diuresis are minimalized and do not influence study outcomes.
* The patient has undergone CVVH for a number of days, ensuring good metabolic control, so that possible short term loss of clearance as a consequence of AV port reversal has no detrimental effects.

Exclusion Criteria:

* pre-existing chronic renal insufficiency requiring dialysis
* chronic immunosuppression
* liver cirrhosis Child-Pugh C
* severe or shock-related hepatitis
* Pregnancy
the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy

This study intends to apply prospective, open, single-center, randomized controlled study to evaluate the cognitive status of patients with Idiopathic membranous nephropathy and the influence of different treatment schemes on the cognitive status of patients with Idiopathic membranous nephropathy, and explore the possible pathophysiological mechanism by using brain magnetic resonance imaging technology.

Proteinuia is an independent risk factor for cognitive dysfunction and dementia. There is no relevant research on whether patients with Idiopathic membranous nephropathy with normal renal function are complicated with cognitive impairment. In the process of clinical diagnosis and treatment, it was observed that the cognitive function of patients with Idiopathic membranous nephropathy decreased significantly after treatment compared with that before treatment. However, there is no clinical study to confirm this phenomenon at present, and the causes of cognitive function damage are not clear. This study intends to apply prospective, open, single-center, randomized controlled study to evaluate the cognitive status of patients with Idiopathic membranous nephropathy and the influence of different treatment schemes on the cognitive status of patients with Idiopathic membranous nephropathy, and explore the possible pathophysiological mechanism by using brain magnetic resonance imaging technology, so as to fill the research gap of clinical cognitive status of Idiopathic membranous nephropathy and provide theoretical basis for better clinical treatment scheme selection and prevention of cognitive impairment.

Eligibility Criteria:
Inclusion Criteria:

* Patients with nephrotic syndrome and normal renal function.
* Patients with idiopathic membranous nephropathy diagnosed by pathology.
* not received hormone or other immunosuppressive treatment in the past six months.

Exclusion Criteria:

* Unable to treat patients with hormones and immunosuppression.
* Patients with definite intracranial diseases such as previous cerebral infarction and cerebral hemorrhage;
* Patients who have been diagnosed with cognitive decline or dementia in the past;
* Patients with claustrophobia or have other contraindications for magnetic resonance imaging, such as pacemakers and metal foreign bodies in the body.
* Pregnant and lactating women
Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, Mainland China

The surveillance of influenza virus among children with febrile reparatory complaints attending the pediatric clinic in Shantou is an epidemiologic study to identify the type (influenza A or B) and the subtype of Influenza A of the isolates from children with febrile respiratory complaints who attend the pediatric clinic of the first Affiliated Hospital, Shantou University Medical College, Shantou Guangdong, China. Also this study investigates the genetic composition of all segments of isolated strains using standard molecular techniques and to make available the new strains of influenza viruses isolated from such children for the formulation of influenza vaccines. Clinical manifestation of the respiratory illness is recorded and single nasopharyngeal swab is obtained from eligible children. Viral culture is performed on the nasopharyngeal secretions. If influenza is isolated, this is characterized if it belongs to influenza A or B. If the virus is characterized as influenza A, further antigenic studies is done to determine subtype of influenza. Viral isolates is further studied to determine the genetic composition of the virus. Information obtained from the viral isolates is shared with the WHO and the CDC.

OBJECTIVES

Primary objective:

* To identify the type (Influenza A or B) and the subtype of Influenza A of the isolates from children with febrile respiratory complaints who attend the pediatric clinic of the First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, China.

Secondary objectives

* To investigate the genetic composition of all segments of isolated strains using standard molecular techniques.
* To make available the new strains of influenza viruses isolated from such children for the formulation of influenza vaccines.

Eligibility Criteria:
Inclusion Criteria:

* Age: 0 day to 18 years.
* Patient was seen at the pediatric clinic of the First Affiliated Hospital within 7 days of the onset of signs and symptoms of febrile respiratory illness suspected to be of viral origin (temperature \> 37.7ºC or reliable history of fever before being examined, and respiratory symptoms and signs such as cough, sore throat, and coryza).
* Parents agree to a nasopharyngeal specimen being taken by swab from their child.

Exclusion Criteria:

* Patient is too ill to tolerate a nasopharyngeal specimen swab.
A Prescription Audit of Inpatient Department of Super Speciality Hospital in National Capital Region of India

Prescription auditing is the art to check the detailing, compatibility and performance of the generated prescription from the physician to the pharmacist and patient, by means of the WHO checklist for prescription auditing. An audit is defined as the review and evaluation of the healthcare procedures and documentation to compare the quality of care provided, with accepted standards.

In this study, we will collect In-patient prescriptions from Fortis Hospital. And it will be evaluated for 13 list out parameters i.e Hospital unique ID, patient name, age, sex, weight, date of consultation, cleanliness and legibility, brief history, allergies, clinical examination, presumptive or definite diagnosis, medicine prescribed by generic name, dose, duration, history of a previous adverse event, appropriate abbreviations used, drug-drug interaction, drug duplication, doctor name, registration number and signature. The study is analyzed by Statistical Process Control (SPC).

Aim of the study:

The aim of the study is to evaluate the quality of the prescription provided to the inpatient.

Objectives of the study:

To study the quality of good prescription In minimization of prescription errors and medication errors Also to comply with good clinical practice Enhancement of patient safety In the maintenance of rational prescribing To study the quality of care provided by the hospital to the patient

Plan of study:

To select the patient based on inclusion and exclusion criteria To collect the information from IP prescription and drug chart To identify prescribing errors and medication error To study the management of good prescription

Methodology:

Study Sites: Fortis Hospital, Noida, Uttar Pradesh (INDIA) Study Design: Observational cohort study Study Duration: 2 months (March, 2023 and May, 2023)

Study Sites: Fortis Hospital, Noida, Uttar Pradesh (INDIA) Study Design: Observational cohort study Study Duration: 2 months (March, 2023 and May, 2023)

Subject Eligibility:

1. Inclusion Criteria Participants who are willing to participate Participants who are admitted in the in-patient department Participants admitted during the study period Participants who have a prescription which is legible and complete
2. Exclusion Criteria Participants who are unwilling to provide the required information Participants who are not admitted the in-patient department Participants whose prescription is not legible and competent
3. Source of the data: Review of In-patient prescription

Sample Size:

300 prescriptions

Eligibility Criteria:
Inclusion Criteria:

* Participants who are willing to participate
* Participants who are admitted in the in-patient department
* Participants admitted during the study period
* Participants who have a prescription which is legible and complete

Exclusion Criteria:

* Participants who are unwilling to provide the required information
* Participants who are not admitted the in-patient department
* Participants whose prescription is not legible and competent
Endothelin-1 as a Potential Trigger of Migraine Aura

One third of migraine patients experience aura, i.e. dramatic, transient neurological symptoms, most often in the form of visual disturbances, that usually appear before the onset of migraine headache. The likely underlying mechanism of aura is known as cortical spreading depression, a wave of changes in electrical activity that slowly spreads in the outermost layer of the brain. It is currently not known what causes the aura to initiate in patients or what the relationship is between aura and migraine headache, e.g. if treatment targeted at aura mechanisms will prevent subsequent headache. Due to the short-lasting and unpredictable nature of aura, the only possible approach for systematic investigations is to experimentally trigger aura, but currently no method for aura-triggering is available.

The overall goal of the proposed project is to reveal the earliest mechanisms of the migraine attack by investigating the initiating factors of aura in the migraine brain.

Current animal evidence indicates that infusion of endothelin-1 (ET-1), a naturally occurring signaling molecule released from blood vessels, is safe and very likely to trigger migraine aura in patients.

In this project the investigators aim to study the effects of ET-1 on the human brain, to investigate aura-inducing effects of ET-1 in patients and to develop a safe and reliable method for the experimental induction of migraine aura using ET-1.


Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 40 years
* Diagnosis of migraine with typical aura (patient group only)
* Attacks of migraine with aura at least once per month on average (patient group only)
* No history or family history of migraine (healthy subject group only)
* Use of safe contraception (women of fertile age only)

Exclusion Criteria:

* Tension-type headache more than one day per month on average
* Any other primary headache disorder
* Daily intake of medication
* Daily smoking during the past 5 years
* Pregnant or breastfeeding women
* Hypertension on the experimental day (systolic BP\>150 mmHg or diastolic BP\> 100 mmHg)
* History of any cardiovascular disease including cerebrovascular disease
* History of diabetes or hypercholesterolemia
* ECG changes suggestive of ischemia
* Contraindications of MRI
Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia

Otherwise healthy women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during preeclampsia and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women.

The purpose of this study is to examine differences in the microvascular balance of angiotensin II receptors women who have had preeclampsia. This will help the investigators better understand the mechanisms of dysregulated angiotensin II receptors in formerly preeclamptic women, and how activation or inhibition of these receptors may restore microvascular function.

In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.


Eligibility Criteria:
Inclusion Criteria:

* women who had preeclampsia and women who did not have preeclampsia
* 12 weeks to 5 years postpartum
* 18-45 years old

Exclusion Criteria:

* history of hypertension or metabolic disease before pregnancy
* history of gestational diabetes or gestational hypertension
* skin diseases
* current tobacco use
* current antihypertensive medication
* statin or other cholesterol-lowering medication
* currently pregnant or planning to become pregnant
* body mass index less than \<18.5 or \>30 kg/m2
* allergy to materials used during the experiment.(e.g. latex),
* known allergy to study drugs
Electrolysis Technique vs Manual Therapy in Pelvic Pain

Pelvic floor muscle physical therapy is recommended in clinical guidelines for women dyspareunia and pelvic pain. This study compare pelvic floor manual therapy and intratissue percutaneous electrolysis (EPI) technique in the treatment of pelvic pain in women with dyspareunia. Half of participants will receive pelvic floor manual therapy while the other half will receive intratissue percutaneous electrolysis technique.

Dyspareunia is painful sexual intercourse and causes could be related to musculoskeletal pelvic floor muscles disorders (tenderness, trigger points, scars). There is evidence that manual therapy and intratissue percutaneous electrolysis can be effective for musculoskeletal pain disorders affecting muscles, tendons and fascias of the extremities but they have not been evaluated in pelvic floor muscle pain syndrome. The aim of this study is to compare manual therapy and EPI in the treatment of pelvic pain in women with dyspareunia.

Pelvic floor manual therapy is a clinical approach utilizing specifics hands-on mobilizing techniques to treat soft tissues. Pelvic floor mobilization is a slow controlled process of soft-tissue (myofascial) stretching intended to improve bio-mechanical elasticity.

EPI technique consists in an ultrasound-guided application of a galvanic electrolytic current that causes a controlled local inflammatory process in the target tissue. This allows for phagocytosis and the subsequent regeneration of the affected tissue.

Eligibility Criteria:
Inclusion Criteria:

* women with pain in the perineal area at an average intensity of 5 or more on the Numerical Rating Scale (NRS) during penetration or during pelvic examination, which is indicative of moderate to severe pain
* At least three months postpartum or any gynecology surgery

Exclusion Criteria:

* pregnancy
* active urinary or vaginal infection
* pelvic pathology associated with a lower genital pain problem (e.g. deep dyspareunia) and constant, spontaneous vulvar pain
* younger than 18 or older than 65 years
* previous interventions with steroid injections
* fibromyalgia syndrome
A Randomized Controlled Trial on Antibiotic Prophylaxis in Children With Vesico-Ureteral Reflux

The aim of this study is to assess the effectiveness of antibiotic prophylaxis in preventing pyelonephritis and in avoiding the appearance of new scars in a sample of children under 36 months with vesico-ureteral reflux (VUR).

In recent years, the effectiveness of continuous antibiotic prophylaxis in children with vesico-ureteral reflux (VUR) has been intensely discussed. The question is not only whether antibiotics are effective in preventing recurrent urinary tract infections (UTI), but also whether they alter the natural history of disease and help to prevent the appearance of new kidneys scars. The evidence on the effectiveness of antibiotic prophylaxis is scanty: randomised controlled trials (RCT) published until now are poorly designed and carried out in very heterogeneous samples of children, i.e. spanning from 6 months to 14-18 years of age and pooling patients with and without VUR. A recently updated Cochrane Systematic Review concludes that high quality RCTs are needed to determine the effectiveness of long-term antibiotics for the prevention of UTIs in susceptible children. Moreover, the presence of VUR has not been firmly shown to be a risk factor for recurrence of pyelonephritis, and a direct association between VUR and the presence of scars or the appearance of new scars has not been demonstrated; there is just an association between VUR of grade IV-V and prenatal renal dysplasia, almost exclusively in male infants. In spite of this uncertainty, several practice guidelines recommend long term antibiotic prophylaxis in children with different degrees of VUR.

The aim of this study is to assess the effectiveness of antibiotic prophylaxis in preventing pyelonephritis and in avoiding the appearance of new scars in a sample of children under 36 months with VUR.

Comparison: In a multicentre trial, 100 patients with VUR diagnosed with cystourethrography after a first episode of acute pyelonephritis or for prenatal evidence of pyelectasia will be assigned randomly to receive prophylaxis or not. Randomization will be carried out using a centralized minimization procedure to balance for sex, age group and VUR grade.

Eligibility Criteria:
Inclusion Criteria:

* presence of vesico-ureteral reflux (VUR) grade II, III or IV, based on the International Classification, mono or bilateral, diagnosed between one day and 30 months of age after a first episode of acute pyelonephritis, or after birth during diagnostic procedures planned as a consequence of prenatal ultrasonographic evidence of pyelectasia.

Exclusion Criteria:

* previous episodes of urinary tract infection (UTI), even if only suspected (e.g. an episode of fever treated with antibiotics without performing urine culture);
* VUR grade I, because of the high probability of rapid spontaneous resolution;
* VUR grade V, as requested by the Technical Scientific Committee, concerned by the high incidence of associated renal dysplasia;
* recurrence of acute pyelonephritis before the first dimercaptosuccinic acid (DMSA) renal scan, if this was positive for scars.